Gladstone Institutes

Gladstone's Deepak Srivastava Honored as Most Admired CEO by San Francisco Business Times

Retrieved on: 
금요일, 5월 10, 2024
Genetic engineering, Patient, Cardiovascular disease, Faculty, Doctor of Philosophy, UC, Immunology, Science, Heart, Heart failure, Therapy, Disease, Health, SAN, Hospital, MD, AI, Trust, Research, Growth, Gladstone Institutes, Neurology, Drug discovery, Medicine, Data science, DSM-IV codes, Regenerative medicine, Virology, American City Business Journals, Biotechnology, Nobel, Cardiology, Gene editing, Management

SAN FRANCISCO, May 10, 2024 /PRNewswire/ -- The San Francisco Business Times has named Gladstone Institutes President Deepak Srivastava, MD, as one of the Most Admired CEOs among Bay Area businesses and nonprofits. In an article now appearing in the weekly publication, Srivastava is noted for his inspiring leadership style and ability to successfully navigate both the nonprofit research landscape and the startup biotech world.

Key Points: 
  • SAN FRANCISCO, May 10, 2024 /PRNewswire/ -- The San Francisco Business Times has named Gladstone Institutes President Deepak Srivastava, MD, as one of the Most Admired CEOs among Bay Area businesses and nonprofits.
  • Additionally, he is a professor at UC San Francisco and an attending physician in pediatric cardiology at UCSF Benioff Children's Hospitals.
  • "The Bay Area is a beacon for the world's business elite, so to be named among the San Francisco Business Times' most admired leaders is one of the best compliments I could receive," Srivastava says.
  • The San Francisco Business Times will honor Srivastava at its Most Admired CEOs gala on May 16.

A New Therapeutic Target for Traumatic Brain Injury

Retrieved on: 
금요일, 4월 19, 2024
Alzheimer's disease, Brain, Inflammation, Coagulation, Mutation, Traffic barrier, Bleeding, Mouse, Skull, Explosion, Gladstone Institutes, Fibrin, Blood, Impulsivity, Research, Accident, Trauma, Doctor of Philosophy, Depression, Life, Brain damage, Head injury, Injury, Patient, DSM-IV codes, Multiple sclerosis, Neurology, Neuron, Traumatic brain injury, Immune system, Journal, Frasier, SAN, Disability, Vaccine

SAN FRANCISCO, April 19, 2024 /PRNewswire/ -- For the roughly 1.5 million Americans per year who survive a traumatic brain injury, health outcomes vary widely. Not only can these injuries lead to a loss of coordination, depression, impulsivity, and difficulty concentrating, but they come with an amplified risk for developing dementia in the future.

Key Points: 
  • SAN FRANCISCO, April 19, 2024 /PRNewswire/ -- For the roughly 1.5 million Americans per year who survive a traumatic brain injury, health outcomes vary widely.
  • "We knew that a specific blood protein, fibrin, was present in the brain after traumatic brain injury, but we didn't know until now that it plays a causative role in brain damage after injury," says Ryu, who led the study that appears in the Journal of Neuroinflammation.
  • But in this case, the traumatic brain injury itself causes the blood to leak into the brain.
  • They also produced three-dimensional imaging of a whole intact mouse brain, showing blood-brain barrier leaks and abundant fibrin in traumatic brain injury.

Biswas Family Foundation, Milken Institute Announce $15 Million in Funding for Research at the Intersection of AI and Health

Retrieved on: 
화요일, 3월 12, 2024
Technology, General Health, Infectious Diseases, Foundation, Philanthropy, Science, Biotechnology, Health, Health Technology, Other Philanthropy, Other Science, Research, Other Technology, Other Health, Pharmaceutical, Artificial Intelligence, Oncology, Gladstone Institutes, Diagnosis, Health informatics, Harvard Medical School, Computational biology, SPARC, Transformative use, Test management, Computer science, Data science, Disease, Assistant, Massachusetts Institute of Technology, Associate, Chatbot, Partnership, Genetics, Patient, Common, Artificial intelligence, AI, Doctor of Philosophy, Interpretation, Investment, Stanford University, Milken Institute, Genetic distance, Medical device

The Biswas Family Foundation , in partnership with the Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC) , is pleased to announce the inaugural recipients of the Transformative Computational Biology Grant Program .

Key Points: 
  • The Biswas Family Foundation , in partnership with the Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC) , is pleased to announce the inaugural recipients of the Transformative Computational Biology Grant Program .
  • Five multidisciplinary research teams will receive nearly $14 million total in grant funding for projects aiming to drive translational impact and the advancement of artificial intelligence (AI) models in clinical settings for diagnosis and treatment.
  • Additional support to enhance AI and computational biology research, inclusive of a gift to the Arc Institute , marks a total of $15 million in giving for the Biswas Family Foundation for this interdisciplinary field, and the beginning of more support.
  • To learn more about the Transformative Computational Biology Grant Program and to read the Giving Smarter Guide, visit: https://bit.ly/3Vae8Kq .

UCSF QBI and the Department of Psychiatry and Behavioral Sciences Announce Breakthrough Research Findings in the Molecular Understanding of Autism

Retrieved on: 
월요일, 12월 4, 2023
Research, Neurology, Genetics, Clinical Trials, Biometrics, Biotechnology, General Health, Pharmaceutical, Health, Science, Sequence, ASD, Anatomy, School, Associate, Brain, Chemistry, Senior, Gladstone Institutes, Gene, Proteomics, Mass spectrometry, Quantitative Biosciences Institute, Spectrum, Protein, UCSF, Doctor of Philosophy, DSM-IV codes, Neuron, Psychiatry, University, Therapy, MD, Behavioural sciences, UCL, Neurogenesis, CRISPR, BioRxiv, SSD, Manuscript, QBI, Vaccine, Pharmacy, Neurosurgery

The Quantitative Biosciences Institute (QBI), in collaboration with the Department of Psychiatry and Behavioral Sciences, at the University of California, San Francisco (UCSF), today reported new breakthrough research findings in the understanding of autism spectrum disorder (ASD).

Key Points: 
  • The Quantitative Biosciences Institute (QBI), in collaboration with the Department of Psychiatry and Behavioral Sciences, at the University of California, San Francisco (UCSF), today reported new breakthrough research findings in the understanding of autism spectrum disorder (ASD).
  • Belinda Wang, MD, Ph.D., Rasika Vartak, Ph.D., Fima Zaltsman, Ph.D., and Zun Zar Chi Naing, Ph.D. are co-first authors of the manuscript.
  • Their findings provide unprecedented insights into the molecular mechanisms of a subset of individuals with ASD who carry specific genetic mutations, serving as a new platform for desperately needed therapeutics development.
  • QBI’s convergent biological systems approach that formed the basis of this study can be applied to virtually any disease area.

L'ORÉAL USA ANNOUNCES 2023 FOR WOMEN IN SCIENCE AWARDEES, MARKING 20-YEAR COMMITMENT TO WOMEN IN STEM

Retrieved on: 
월요일, 11월 13, 2023
Woman, Biomedical engineering, Engineering, Gladstone Institutes, NASEM, Infection, Uterus, Johns Hopkins University, Uterine fibroid, Fibrosis, Fertility, Gene editing, Data science, Diplomacy, Health, National academy, Neuroscience, Ageing, California Institute of Technology, Communication, Brain cell, Female, Spina bifida, AAAS, Medicine, Physics, Khwarizmi International Award, DSM-IV codes, Mentorship, Equity, Animal, University, Bangladesh Technical Education Board, University of North Carolina, Cell, UNESCO, Brain, Research, Microbiology, Biotechnology, Fungus, Fellow, CBS, Human, Survival, Neoplasm, Biology, Pharmaceutical industry, Management, STEM, Science

NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Today, L'Oréal USA announced the recipients of its 2023 For Women in Science (FWIS) Fellowship program, which grants awards annually to five female postdoctoral scientists to support their research endeavors. This year marks L'Oréal USA's 20th anniversary of helping to advance women in STEM fields through its FWIS program, which has provided more than $5 million in grants to support the work of innovative women scientists.

Key Points: 
  • "L'Oréal USA is proud to recognize this 20th Anniversary milestone of the For Women in Science program.
  • The L'Oréal USA FWIS philanthropic program embodies L'Oréal's fundamental belief in the indispensable connection between science and women.
  • The L'Oréal USA program includes a requirement to ensure recipients are committed to serving as role models for younger generations.
  • For more information about the L'Oréal USA 2023 For Women in Science Fellows or to apply for the L'Oréal For Women in Science 2024 program, please visit: loreal.com/en/usa/pages/group/fwis/ .

A Quarter Century of Disease-Focused Neuroscience

Retrieved on: 
화요일, 10월 3, 2023
Epilepsy, San Francisco, Huntington's disease, Central nervous system, Therapy, Prevalence, Stanford University, Apolipoprotein, Biogen, Biotechnology, University of California, San Francisco, Brain, Research, DSM-IV codes, Multiple sclerosis, Fairmont San Francisco, AstraZeneca, Eli Lilly, Neuroscience, Amyloid, Parkinson's disease, UC, Myenteric plexus, Patient, Tau, Trustee, SAN, Gladstone Institutes, Spectrum, Blood, Weill Cornell Medicine, Sanofi, BMS, Merck, Takeda Pharmaceutical Company, Disease, Pharmaceutical industry, Vaccine, Nursing, Lundbeck, Alzheimer's disease, Genentech, MD, William Ewart Gladstone

SAN FRANCISCO, Oct. 3, 2023 /PRNewswire/ -- A quarter century ago, in September 1998, Gladstone Institutes launched the Gladstone Institute of Neurological Disease. In 2023, it brought together investigators and alumni to celebrate the institute's 25th anniversary, reflect on landmark scientific achievements, and look ahead at the future of disease-focused neuroscience.

Key Points: 
  • SAN FRANCISCO, Oct. 3, 2023 /PRNewswire/ -- A quarter century ago, in September 1998, Gladstone Institutes launched the Gladstone Institute of Neurological Disease.
  • In 2023, it brought together investigators and alumni to celebrate the institute's 25th anniversary, reflect on landmark scientific achievements, and look ahead at the future of disease-focused neuroscience.
  • As populations around the world are living longer, aging-related neurodegenerative disorders have been rising in prevalence at an unprecedented pace.
  • These landmark discoveries, and many others, were presented on September 15, 2023, as part of the symposium "Disease-Focused Neuroscience: From Discovery to Translation."

UCSF QBI, University College London, and Mount Sinai Identify Shared Molecular Mechanisms Across SARS-CoV-2 Variants that Allow Virus to Thrive Despite Vaccination

Retrieved on: 
목요일, 9월 21, 2023
Vaccine, San Francisco, Infection, University College London, UCL, Cell Host & Microbe, Omicron, Senior, Life, HIV, Icahn School of Medicine at Mount Sinai, University, SARS-CoV-2, System, ORF6, COVID-19, Survival, University of California, San Francisco, Emerging Pathogens Institute, Viral, Research, Mount Sinai, Cell, Doctor of Philosophy, Delta, Assistant, Global Health, QBI, Genetics, Pandemic, G.H. Raisoni Department of Microbiology and Biotechnology, Quantitative Biosciences Institute, UC, UCSF, Laboratory, Pathology, SAN, CELL, School, Immune system, Gladstone Institutes, UCLA, Health, Adolfo, Virus, Pharmacy, Microbiology, Alpha

SAN FRANCISCO and LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- In a study published online in CELL today, scientists at UCSF QBI, University College London and the Icahn School of Medicine at Mount Sinai reported breakthrough findings on convergent evolutionary mechanisms shared by COVID-19 variants, allowing them to overcome both adaptive and innate immune system barriers. In the paper titled, SARS-CoV-2 Variants Evolve Convergent Strategies to Remodel the Host Response, scientists carried out an unprecedented, systematic comparative study using the most infectious COVID-19 variants, namely Alpha, Beta, Gamma, Delta and Omicron to identify specific viral mutations responsible for hijacking a common host pathway, thereby leading to increased transmissibility, infectivity and survival. Specifically, they discovered a convergence in potent suppression of interferon-stimulated genes through several viral proteins, including Orf6 and Orf9b, which serve as innate immune antagonist proteins capable of blocking innate host immune response.

Key Points: 
  • The award, which included a $200,000 prize, is intended to provide support for his vision for progress against pandemic threats.
  • “Unfortunately, we continue to see new mutations and strains of SARS-CoV-2 despite innovations in new vaccines,” said Dr. Krogan, who founded the QBI Coronavirus Research Group (QCRG).
  • This finding is consistent with our investigation of early SARS-CoV-2 variants where certain viral proteins were highly expressed in infected cells which helped the virus infect our cells.
  • Their analysis pinpointed cellular pathways that are similarly modulated across variants during infection and represent putative targets for pan-coronavirus antivirals.

Lego-Like Gene Editing Tool Lets Researchers Improve Cancer Immunotherapy

Retrieved on: 
목요일, 9월 14, 2023
Lymphoma, Molecular biology, War, DNA, CRISPR, Brain, Stanford School, Therapy, TFAP4, Gene editing, Bone marrow, University of California, San Francisco, Cancer, Doctor of Philosophy, BATF, CAR, MD, UCSF, Patient, Pathology, SAN, Canadian Aviation Regulations, William Ewart Gladstone, Lego, Atlas, Gladstone Institutes, Leukemia, Gene, Factorization of polynomials, Vaccine, Pharmaceutical industry, Marson, Cell

SAN FRANCISCO, Sept. 14, 2023 /PRNewswire/ -- In recent years, scientists have used gene modification technologies to reprogram immune cells into therapeutics that can attack cancers. But such immunotherapies don't work for all patients or all cancer types, and screening through every possible combination of genetic changes that might improve these reprogrammed immune cells is a daunting and slow task.

Key Points: 
  • When a T cell recognizes a cancer cell as foreign, through a receptor on its surface, it targets the cancer cell for destruction.
  • The technology combines multiple genes into long stretches of DNA for use in a CRISPR gene editing platform.
  • An easy-to-read DNA barcode on each ModPoKI-generated set of genes let them track which gene combination led to improved T cells.
  • "In the lab, the ModPoKI sequence with BATF and TFAP4 made CAR T cells show potential to improve anti-tumor activity," says Marson.

Breaking Down the Science of the Blood-Brain Barrier

Retrieved on: 
금요일, 9월 1, 2023
Yang, White House, Communication, Myenteric plexus, Stanford University, Politics, Neurodegenerative disease, Policy, University of California, San Francisco, Ageing, Traffic barrier, Brain, Research, Cell, Inflammation, Doctor of Philosophy, DSM-IV codes, Movement, White, Science, Thought, Data science, Dementia, Protein, Animal, Gladstone Institutes, Patient, UCSF, Risk, SAN, Engineering, Physics, Anatomy, Neurology, Observation, Diagnosis, Atlas, Environment, Gene, Alzheimer's disease, Massachusetts Institute of Technology School of Science, Disease, Mobile phone, Medical imaging, Nursing, Medical device, Vaccine, MD, William Ewart Gladstone

SAN FRANCISCO, Sept. 1, 2023 /PRNewswire/ -- For decades, many scientists have described the blood-brain barrier—a tight network of cells that separates the brain from the blood—as a nearly impenetrable border wall. But Andrew C. Yang, PhD, who is joining Gladstone Institutes as an assistant investigator, thinks there's more to it than that. He likens the blood-brain barrier to a family home.

Key Points: 
  • "I think we'll come to appreciate that, similarly, the blood-brain barrier maintains a dynamic and sophisticated dialogue with other parts of the body."
  • His research could inform the design of new drugs that can efficiently cross the blood-brain barrier, a current impediment to treating many brain conditions.
  • At the time Yang was completing his graduate studies, it remained difficult to identify individual proteins crossing the blood-brain barrier.
  • At Gladstone, Yang is looking forward to collaborating with researchers across neuroscience, immunology, and data science as he tackles the large questions of how the blood-brain barrier relates to disease.

How Unique Immune Cells Can Recognize--and Destroy--Tumors

Retrieved on: 
수요일, 8월 30, 2023
San Francisco, CRISPR, University, Nature, Biochemistry, Murad, Hematology, University Medical Center, Neoplasm, Marson, University of California, San Francisco, Cancer, Mamedov, Cell, Doctor of Philosophy, Thought, University Medical Center Utrecht, Gamma delta T cell, UC, MD, Patient, Physician, SAN, Immune system, Butyrophilin, Biology, Bacteria, Gladstone Institutes, Virus, Gene, Genome, Vaccine, Medical imaging, William Ewart Gladstone

SAN FRANCISCO, Aug. 30, 2023 /PRNewswire/ -- Gamma delta T cells, a special type of cell in the immune system, are incredibly effective at recognizing and killing cancer cells. Cancer patients with higher levels of these T cells in their tumors tend to fare better than those with lower levels. But scientists have struggled to understand exactly how gamma delta T cells can recognize cancerous cells, and how new cancer therapies may be able to take advantage of these powerful immune cells.

Key Points: 
  • New study explains how understudied cells in the immune system, called gamma delta T cells, can target cancer cells for destruction
    SAN FRANCISCO, Aug. 30, 2023 /PRNewswire/ -- Gamma delta T cells, a special type of cell in the immune system, are incredibly effective at recognizing and killing cancer cells.
  • But scientists have struggled to understand exactly how gamma delta T cells can recognize cancerous cells, and how new cancer therapies may be able to take advantage of these powerful immune cells.
  • Now, researchers at Gladstone Institutes and UC San Francisco have pinpointed conditions that enable gamma delta T cells to identify cancer cells.
  • "In healthy cells, butyrophilin is invisible to gamma delta T cells, so that T cells don't start killing them," explains Mamedov.